Institut de Recherche Contre les Cancers de l'Appareil Digestif (IRCAD), Strasbourg, France.
Institut hospitalo-universitaire (IHU), Institute for Minimally Invasive Hybrid Image-Guided Surgery, Université de Strasbourg, 1 Place de l'Hôpital, 67000, Strasbourg, France.
Hepatol Int. 2019 Sep;13(5):546-559. doi: 10.1007/s12072-019-09973-0. Epub 2019 Aug 31.
Radiomics is an emerging field which extracts quantitative radiology data from medical images and explores their correlation with clinical outcomes in a non-invasive manner. This review aims to assess whether radiomics is a useful and reproducible method for clinical management of hepatocellular carcinoma (HCC) by reviewing the strengths and weaknesses of current radiomics literature pertaining specifically to HCC. From an initial set of 48 articles recovered through database searches, 23 articles were retained to be included in this review after full screening. Among these 23 studies, 7 used a radiomics approach in magnetic resonance imaging (MRI). Only two studies applied radiomics to positron emission tomography-computed tomography (PET-CT). In the remaining 14 articles, a radiomics analysis was performed on computed tomography (CT). Eight studies dealt with the relationship between biological signatures and imaging findings, and can be classified as radiogenomic studies. For each study included in our review, we computed a Radiomics Quality Score (RQS) as proposed by Lambin et al. We found that the RQS (mean ± standard deviation) was 8.35 ± 5.38 (out of a possible maximum value of 36). Although these scores are fairly low, and radiomics has not yet reached clinical utility in HCC, it is important to underscore the fact that these early studies pave the way for the radiomics field with a focus on HCC. Radiomics is still a very young field, and is far from being mature, but it remains a very promising technology for the future for developing adequate personalized treatment as a non-invasive approach, for complementing or replacing tumor biopsies, as well as for developing novel prognostic biomarkers in HCC patients.
放射组学是一个新兴领域，它从医学图像中提取定量放射学数据，并以非侵入性的方式探索它们与临床结果的相关性。本综述旨在通过评估当前专门针对肝细胞癌 (HCC) 的放射组学文献的优缺点，评估放射组学是否是一种有用且可重复的 HCC 临床管理方法。通过数据库搜索共检索到 48 篇文章，经过全面筛选后保留了 23 篇文章纳入本综述。在这 23 项研究中，有 7 项使用了磁共振成像 (MRI) 的放射组学方法。只有两项研究将放射组学应用于正电子发射断层扫描-计算机断层扫描 (PET-CT)。在其余的 14 篇文章中，对计算机断层扫描 (CT) 进行了放射组学分析。有 8 项研究涉及生物学特征与影像学发现之间的关系，可归类为放射基因组学研究。对于我们综述中纳入的每项研究，我们计算了 Lambin 等人提出的放射组学质量评分 (RQS)。我们发现 RQS（平均值 ± 标准差）为 8.35 ± 5.38（满分 36 分）。尽管这些分数相当低，放射组学尚未在 HCC 中达到临床实用性，但重要的是要强调这些早期研究为放射组学领域铺平了道路，重点是 HCC。放射组学仍然是一个非常年轻的领域，远未成熟，但它仍然是一种非常有前途的技术，可用于未来开发适当的个体化治疗方法，作为一种非侵入性方法，用于补充或替代肿瘤活检，以及开发 HCC 患者的新型预后生物标志物。
